| Bioactivity | Iopromide is a non-ionic, monomeric, iodine-based contrast medium for intravascular administration. | ||||||||||||
| In Vivo | Contrast medium-induced nephropathy can be induced by tail intravenous administration of iopromide[1]. In randomized controlled trials, the global image quality and diagnostic quality with iobitridol does not differ from those with other low-osmolar contrast media (iohexol, iopromide, iopamidol, iomeprol and ioxaglate) or the iso-osmolar contrast medium iodixanol in adults or children undergoing radiographic imaging. Large post-marketing surveillance studies have confirmed that iobitridol produces good or excellent opacification and is an effective contrast agent in the vast majority of patients. Iobitridol is generally well tolerated and had a tolerability profile similar to that of other low-osmolar and iso-osmolar contrast media. Thus, iobitridol is an effective intravascular agent for contrast enhancement in diagnostic imaging[2]. | ||||||||||||
| Name | Iopromide | ||||||||||||
| CAS | 73334-07-3 | ||||||||||||
| Formula | C18H24I3N3O8 | ||||||||||||
| Molar Mass | 791.11 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Jiang W, et al. Breviscapine attenuatted contrast medium-induced nephropathy via PKC/Akt/MAPK signalling in diabetic mice. Am J Transl Res. 2016 Feb 15;8(2):329-41. [2]. McCormack PL, et al. Iobitridol: a review of its use as a contrast medium in diagnostic imaging. Clin Drug Investig. 2013 Feb;33(2):155-66. |